TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tenaya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.38−0.00 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $82.16M
- P/E (TTM)
- –
- Dividend yield
- –
Tenaya Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Market Cap | $84.67M | $166.30M |
| Enterprise Value | $6.57M | $88.19M |
| PB Ratio | 1.22 | 2.03 |
| P/TBV Ratio | 1.22 | 2.29 |
Income (trailing twelve months)
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$105.86M | -$21.40M |
| Pretax Income | -$103.12M | -$14.34M |
| Net Income | -$103.12M | -$22.46M |
| EBITDA | -$98.67M | -$16.91M |
| EPS (Diluted) | -$0.53 | -$0.83 |
Returns
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -121.9% | -53.2% |
| Return on Assets (ROA) | -95.6% | -40.9% |
| Return on Invested Capital (ROIC) | -860.5% | -32.4% |
| Return on Capital Employed (ROCE) | -142.1% | -38.1% |
Balance sheet
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $78.10M | $61.43M |
| Net Cash (Debt) | $78.10M | $15.35M |
| Net Cash Per Share | $0.35 | $0.66 |
| Equity (Book Value) | $69.41M | $49.09M |
| Book Value Per Share | $0.31 | $1.37 |
| Tangible Book Value | $69.41M | $23.52M |
| Working Capital | $66.99M | $76.81M |
Financial position
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.52 | 3.34 |
| Quick Ratio | 4.13 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$52.33M | -$12.35M |
| Capital Expenditures | -$263.00K | -$1.08M |
| Free Cash Flow | -$52.59M | -$20.22M |
| FCF Per Share | -$0.23 | -$0.42 |
Efficiency
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.47M | -$703.34K |
| Employee Count | 70 | 74 |
Dividends and yields
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -121.8% | -23.3% |
| FCF Yield | -62.1% | -8.72% |
Shares
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 224,230,000 | 58,127,000 |
| Shares Change (YoY) | 73.6% | 10.9% |
| Shares Change (QoQ) | 3.33% | 0.54% |
| Float | 166,599,000 | 49,136,700 |
| Shares Held by Insiders | 25.7% | 11.6% |
| Shares Held by Institutions | 24.0% | 59.4% |
Taxes
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Tenaya Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -10.76 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Tenaya Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.